ANTHEM BIOSCIENCES LTD (ANTHEM) financials

ANTHEM BIOSCIENCES LTD (ANTHEM) NSE/BSE financials on Fincrux: quarterly results, profit and loss, cash flow, balance sheet, ratios, and shareholding.

Incorporated in 2006, Anthem BiosciencesLtd is in the business of providing CRDMO services and the manufacture and sale of specialty ingredients.[1]

Market Cap: ₹45,380Cr.
Current Price: ₹806
Stock P/E: 70.7
ROE: 24.3%
ROCE: 32.0%
Book Value: ₹56.7
Dividend Yield: 0.25%
52W High / Low: ₹978/579

In Jun 2026, ANTHEM BIOSCIENCES LTD (ANTHEM) reported sales ₹384 Cr and net profit ₹102 Cr.

Annual TTM: sales ₹1,935 Cr, net profit ₹624 Cr.

Shareholding: Promoters 71.39% (Sep 2026), FIIs 3.79% (Sep 2026), DIIs 12.10% (Sep 2026), Public 12.71% (Sep 2026), No. of Shareholders 1,76,209% (Sep 2026).

ANTHEM quarterly results (₹ Cr.)
Category	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	525	498	479	538	552	417	582	384
Expenses	324	331	281	343	327	254	316	253
Operating Profit	201	167	198	195	226	163	267	131
OPM %	38%	33%	41%	36%	41%	39%	46%	34%
Other Income	28	24	38	28	54	15	62	29
Interest	3	2	2	2	2	1	2	1
Depreciation	19	20	21	23	24	27	26	22
Profit before tax	207	170	213	199	253	150	301	136
Tax %	18%	25%	42%	25%	22%	25%	30%	25%
Net Profit	170	128	123	148	198	112	212	102
EPS in Rs	3.05	2.29	2.19	2.64	3.53	2.00	3.77	1.81
Raw PDF	—	—	—	—	—	—	—	—

ANTHEM profit and loss (₹ Cr.)
Category	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	633	1,103	1,231	1,057	1,418	1,841	2,089	1,935
Expenses	451	695	666	626	912	1,151	1,238	1,149
Operating Profit	182	408	566	431	505	690	851	787
OPM %	29%	37%	46%	41%	36%	37%	41%	41%
Other Income	21	37	49	139	70	109	158	159
Interest	20	17	10	9	9	9	7	6
Depreciation	62	62	58	64	81	78	100	99
Profit before tax	121	366	547	498	485	711	903	840
Tax %	23%	26%	26%	23%	23%	29%	26%	—
Net Profit	93	271	406	386	375	506	671	624
EPS in Rs	1.70	4.92	7.11	6.76	6.70	9.05	11.94	11.11
Dividend Payout %	0%	0%	0%	0%	0%	0%	17%	—

ANTHEM balance sheet (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	8	8	8	9	114	112	112	112
Reserves	323	413	693	1,347	1,628	1,821	2,361	3,072
Borrowings	192	159	100	35	115	173	113	50
Other Liabilities	194	207	232	228	136	219	249	296
Total Liabilities	718	787	1,034	1,619	1,993	2,324	2,836	3,531
Fixed Assets	316	306	361	329	449	478	624	613
CWIP	12	50	19	153	143	156	58	84
Investments	73	99	209	273	499	472	533	1,380
Other Assets	318	333	444	865	902	1,219	1,620	1,455
Total Assets	718	787	1,034	1,619	1,993	2,324	2,836	3,531

ANTHEM cash flows (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from Operating Activity	196	166	278	333	319	164	300	889
Cash from Investing Activity	-121	-109	-196	-206	-378	-192	-250	-742
Cash from Financing Activity	-65	-48	-63	181	53	-132	-68	-44
Net Cash Flow	9	9	18	308	-6	-159	-18	104
Free Cash Flow	144	119	159	308	145	41	171	753
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit	114%	116%	85%	81%	101%	56%	67%	128%

ANTHEM shareholding pattern (%)
Category	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Promoters	74.69%	74.69%	74.67%	71.42%	71.39%
FIIs	1.66%	1.37%	1.28%	2.57%	3.79%
DIIs	7.21%	7.60%	11.55%	13.48%	12.10%
Public	16.42%	16.34%	12.48%	12.52%	12.71%
No. of Shareholders	2,17,681	1,99,492	1,80,220	1,73,273	1,76,209

ANTHEM key ratios
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	68	61	84	97	95	126	89	100
Inventory Days	123	186	29	52	139	129	167	55
Days Payable	72	87	50	58	77	61	54	32
Cash Conversion Cycle	119	160	63	91	157	194	201	122
Working Capital Days	22	20	27	75	114	129	128	82
ROCE %	—	26%	55%	51%	28%	25%	31%	32%

ANTHEMUpdated 22 Oct 2026, 5:05

Anthem Biosciences Ltd

ANTHEMUpdated 22 Oct 2026, 5:05

Market Cap

₹45,380Cr.

Current Price

₹806

High / Low

₹978/579

Stock P/E

70.7

ROE24.3%

ROCE32.0%

Book Value₹56.7

Face Value₹2.00

Dividend Yield0.25%

About

Incorporated in 2006, Anthem BiosciencesLtd is in the business of providing CRDMO services and the manufacture and sale of specialty ingredients.[1]

Quarterly results

Last reported quarters₹ Cr.

Quarter	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Sep 2024	525	3	324	28	19	207	18	170	3.05
Dec 2024	498	2	331	24	20	170	25	128	2.29
Mar 2025	479	2	281	38	21	213	42	123	2.19
Jun 2025	538	2	343	28	23	199	25	148	2.64
Sep 2025	552	2	327	54	24	253	22	198	3.53
Dec 2025	417	1	254	15	27	150	25	112	2
Mar 2026	582	2	316	62	26	301	30	212	3.77
Jun 2026	384	1	253	29	22	136	25	102	1.81

Profit & loss

Annual statement₹ Cr.

Year	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Mar 2019	626	18	454	21	61	114	32	77	1.41
Mar 2020	633	20	451	21	62	121	23	93	1.7
Mar 2021	1103	17	695	37	62	366	26	271	4.92
Mar 2022	1231	10	666	49	58	547	26	406	7.11
Mar 2023	1057	9	626	139	64	498	23	386	6.76
Mar 2024	1418	9	912	70	81	485	23	375	6.7
Mar 2025	1841	9	1151	109	78	711	29	506	9.05
Mar 2026	2089	7	1238	158	100	903	26	671	11.94
TTM	1935	6	1149	159	99	840	—	624	11.11

Shareholding pattern

As of Sep 2026%

Holder	Share
Promoters	71.39%
FIIs	3.79%
DIIs	12.1%
Public	12.71%

Shareholding trend

Ownership over time%

Quarter	Promoters	FIIs	DIIs	Public
Sep 2025	74.69%	1.66%	7.21%	16.42%
Dec 2025	74.69%	1.37%	7.6%	16.34%
Mar 2026	74.67%	1.28%	11.55%	12.48%
Jun 2026	71.42%	2.57%	13.48%	12.52%
Sep 2026	71.39%	3.79%	12.1%	12.71%

Balance sheet

Assets & liabilities₹ Cr.

Period	Equity Capital	Reserves	Borrowings	Other Liabilities	Total Liabilities	Fixed Assets	CWIP	Investments	Other Assets	Total Assets
Mar 2019	8	323	192	194	718	316	12	73	318	718
Mar 2020	8	413	159	207	787	306	50	99	333	787
Mar 2021	8	693	100	232	1034	361	19	209	444	1034
Mar 2022	9	1347	35	228	1619	329	153	273	865	1619
Mar 2023	114	1628	115	136	1993	449	143	499	902	1993
Mar 2024	112	1821	173	219	2324	478	156	472	1219	2324
Mar 2025	112	2361	113	249	2836	624	58	533	1620	2836
Mar 2026	112	3072	50	296	3531	613	84	1380	1455	3531

Cash flows

Operating, investing & financing₹ Cr.

Period	Operating	Investing	Financing	Net cash flow
Mar 2019	196	-121	-65	9
Mar 2020	166	-109	-48	9
Mar 2021	278	-196	-63	18
Mar 2022	333	-206	181	308
Mar 2023	319	-378	53	-6
Mar 2024	164	-192	-132	-159
Mar 2025	300	-250	-68	-18
Mar 2026	889	-742	-44	104

Key ratios

Historical financial ratios

Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	68	61	84	97	95	126	89	100
Inventory Days	123	186	29	52	139	129	167	55
Days Payable	72	87	50	58	77	61	54	32
Cash Conversion Cycle	119	160	63	91	157	194	201	122
Working Capital Days	22	20	27	75	114	129	128	82
ROCE %	—	26%	55%	51%	28%	25%	31%	32%

Frequently asked questions

Quick answers about this company's financials on Fincrux

What is the market cap of ANTHEM BIOSCIENCES LTD (ANTHEM)?

The reported market capitalisation for ANTHEM BIOSCIENCES LTD (ANTHEM) is ₹45,380Cr. on Fincrux. Figures may update with market data and filings.

What is the current share price of ANTHEM?

The current price shown for ANTHEM BIOSCIENCES LTD (ANTHEM) on Fincrux is ₹806 with a 52-week high/low of ₹978/579.

What is the P/E ratio of ANTHEM BIOSCIENCES LTD (ANTHEM)?

The stock P/E for ANTHEM BIOSCIENCES LTD (ANTHEM) is 70.7 on Fincrux, with ROE at 24.3% and ROCE at 32.0%.

What were ANTHEM latest quarterly results?

For Jun 2026, ANTHEM BIOSCIENCES LTD (ANTHEM) reported sales ₹384 Cr and net profit ₹102 Cr (figures in ₹ crore unless noted).

What are ANTHEM annual sales and net profit?

For TTM, ANTHEM BIOSCIENCES LTD (ANTHEM) shows sales of ₹1,935 Cr and net profit of ₹624 Cr on the Fincrux profit & loss statement.

Who owns ANTHEM BIOSCIENCES LTD (ANTHEM)?

Latest shareholding for ANTHEM BIOSCIENCES LTD (ANTHEM) on Fincrux: Promoters 71.39% (Sep 2026), FIIs 3.79% (Sep 2026), DIIs 12.10% (Sep 2026), Public 12.71% (Sep 2026), No. of Shareholders 1,76,209% (Sep 2026).

Where can I find ANTHEM BIOSCIENCES LTD (ANTHEM) financials?

ANTHEM BIOSCIENCES LTD (ANTHEM) financials on Fincrux include quarterly results, profit and loss, cash flow, balance sheet, key ratios, and shareholding patterns for NSE/BSE research.

Does Fincrux show ANTHEM balance sheet and cash flow?

Yes. The ANTHEM BIOSCIENCES LTD (ANTHEM) page on Fincrux includes balance sheet, cash flow statements, historical ratios, and ownership trends alongside quarterly and annual results.

Figures in ₹ crore unless noted. Data sourced for research and may lag filings.

Last updated 22 October 2026 at 5:05